Therapeutic potential of endothelin receptor antagonists in diabetes

Bibliography

• BENIGNI A, PERICO N, REMUZZI G: Endothelin antago-nists and renal protection. J. Cardiovasc. Pharmacol (2000) 35 (Suppl. 2):S75–78.
   Google Scholar
• YANAGISAWA M, KURIHARA H, KIMURA S eta].: Anovelpotent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411–415.
   Google Scholar
• INOUE A, YANAGISAWA M, KIMURA S et al.: The humanendothelin family: three structurally and pharmaco-logically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA (1989) 86:2863–2867.
   PubMed Web of Science ®Google Scholar
• KING GL, BROWNLEE M: The cellular and molecular mechanisms of diabetic complications. Endocrinol. Metab. Clin. North Am. (1996) 25:255–270.
   PubMed Web of Science ®Google Scholar
• RUBANYI GM, POLOKOFF MA: Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol. Rev. (1994) 46:325–414.
   PubMed Web of Science ®Google Scholar
• LEVIN ER: Endothelins. N. Engl. J. Med. (1995) 333:356–363.
   PubMedGoogle Scholar
• SIMONSON MS, JONES JM, DUNN MJ: Differential regula-tion of fos and jun gene expression and AP-1 Cis element activity by endothelin isopeptides: Possible implications for mitogenic signalling by endothelin. Biol. Chem. (1992) 267:8643–8649.
   Web of Science ®Google Scholar
• INOUE A, YANAGISAWA M, KIMURA S et al.: The humanendothelin family: Three structurally and pharmaco-logically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA (1989) 86:2863–2867.
   PubMed Web of Science ®Google Scholar
• KIRCHENGAST M MUNTER K: Endothelin-1 andendothelin receptor antagonists in cardiovascular remodelling. PSEBM (1999) 221:312–324.
   PubMedGoogle Scholar
• EMORI T, HIRATA Y, IMAI T et al.: Cellular mechanismsof thrombin on endothelin-1 biosynthesis and release in bovine endothelial cells. Biochem. Pharmacol (1992) 44:2409–2411.
   PubMed Web of Science ®Google Scholar
• KURIHARA H, YOSHIZUMI M, SUGIYAMA T et al.: Transforming growth factor beta stimulates the expression of endothelin mRNA from vascular endothelial cells. Biochem. Biophys. Res. Commun. (1989) 159:1435–1440.
   PubMed Web of Science ®Google Scholar
• MARSDEN PA, BRENNER BM: Transcriptional regulationof the endothelin gene by TNF alpha. Am. J. Physiol (1992) 262:854–861.
   Google Scholar
• MIYAUCHI T, MASAKI T: Pathophysiology of endothelinin the cardiovascular system. Ann. Rev. Physiol (1999) 61:391–415.
   PubMed Web of Science ®Google Scholar
• EMORI T, HIRATA Y, IMAI T, EGUCHI S, KANNO K,MARUMO F: Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosyn-thesis in rat endothelial cells. Endocrinology (1993) 133:2474–2480.
   PubMed Web of Science ®Google Scholar
• IMAI T, HIRATA Y, EMORI T, MARUMO F: Heparin has aninhibitory effect on endothelin-1 synthesis and release by endothelial cells. Hypertension (1993) 21:353–358.
   PubMed Web of Science ®Google Scholar
• GASCI S, WAGNER OF, VIERHAPPER H, NOWOTNY, P,WALDHAUSL W: Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissue may contribute to the overall disposal of the peptide. J. Cardiovasc. Pharmacol. (1992) 19:176–180.
   PubMed Web of Science ®Google Scholar
• SAKURAI T, YANAGISAWA M, MASAKI T: Molecular characterization of endothelin receptors. Trends Pharmacol. Sci. (1992) 13:103–108.
   PubMed Web of Science ®Google Scholar
• ROUX S, BREU V, ERIEL SI, CLOZEL M: Endothelin antagonism with bosentan: a review of potential applications. J. Mol. Med. (1999) 77:364–376.
   PubMed Web of Science ®Google Scholar
• OHLSTEIN EH, DOUGLAS SA: En do th elin -1 modulates vascular smooth muscle structure and vasomotion: implications in cardiovascular pathology. Drug. Dev. Res. (1993) 29:108–128.
   Web of Science ®Google Scholar
• DE NUCCI G, THOMAS R, D'ORLEANS-JUSTE P et al.: Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium derived relaxing factor. Proc. Nad Acad. Sci. USA (1988) 85:9797–9800.
   Google Scholar
• SEO B, OEMAR BS, SIEBENMANN R, VON SEGESSER L,LUSCHER TF: Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation (1994) 89:1203–1208.
   PubMed Web of Science ®Google Scholar
• DOUGLAS SA: Clinical development of endothelin receptor antagonists. Trends Pharmacol. Sci. (1997) 18 (11):408–412.
   PubMed Web of Science ®Google Scholar
• FILEP JG: Endothelin receptor antagonists: New perspectives in endothelin research. Drugs Today (1995) 31(3):155–171.
   Google Scholar
• SCHIFFRIN EL: Endothelin: role in hypertension. Biol. Res. (1998) 31(3):199–208.
   PubMed Web of Science ®Google Scholar
• CODY WL, HE JX, DEPUE PL et al.: Structure-activity relationships of the potent combined endothelin-A/endothelin-B receptor antagonists Ac-DDip 1 6-Leu-Asp-Ile-Trp 21 :Development of endothelin-B receptor selective antagonists. J Med. Chem. (1995) 38(15):2809–2819.
   PubMed Web of Science ®Google Scholar
• AMBERG W, HERGENRODER S, HILLEN H et al.: Discovery and synthesis of (S)-342-(3,4-dimethoxy phenyl) ethoxy]-2-(4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU-302872), a novel orally active mixed ETA/EIB receptor antago-nist. J. Med. Chem. (1999) 42 (16):3026–3032.
   PubMed Web of Science ®Google Scholar
• OKADA M, IKEDA T, OHTA H et al.: J-104132, a potent, orally active, mixed ETA/EIB receptor antagonist, attenuated salt-sensitive hypertension. Jpn. J. Pharmacol (1999) 79 (Suppl. I):281.
   Google Scholar
• ELLIOTT JD, EZEKIEL M, GELLAI M, DOUGLAS SA, OHLSTEIN EH: Antihypertensive effect of the endothelin receptor antagonist SB-209670. Faseb (1994) 8(5):A40.
   Google Scholar
• BECK GR, JR., DOUGLAS SA, ELLIOT JD, OHLSTEIN EH: Agonist-dependent inhibition by peptide and non peptide endothelin receptor antagonists in the rabbit isolated pulmonary artery. J. Cardiovasc. Pharmacol (1995) 26 (Suppl. 3):S385–S388.
   Google Scholar
• NABOKOV AV, AMANN K, WESSELS S, MUNTER K, WAGNER J, RITZ E: Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int. (1999) 5 5 (2):512–519.
   Google Scholar
• OPGENORTH TJ, ADLER AL, CALZADILLA SV, CHIOU WJ:Pharmacological characterization of A-127722: An orally active and highly potent ET (A)-selective receptor antagonist. J. Pharmacol. Exp. Ther. (1996) 276 (2):473–481.
   PubMed Web of Science ®Google Scholar
• WU C, CHAN MF, STAVROS F, RAJU B, OKUN I, CASTILLORS: Structure-activity relationships of N2-ary1-3-(isoxazolysulfamoy1)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists 1.j Med. Chem. (1997) 40(10:1682–1689.
   Google Scholar
• LIU G, HENRY KJ, SZCZEPANKIEWICZ BG et al: Highlyselective endothelin antagonists for ETa receptor: synthesis and structure-activity relationships. ACS 213th. San Francisco, USA (1997) :MEDI193.
   Google Scholar
• BATTISTINI B, WARNER TD, FOURNIER A, VANE JR: Comparison of PD-145065 and Ro-46-2005 as antago-nists of contractions of guinea-pig airways induced by en do th elin -1 or IRL-1620. Eur. j Pharmacol (1994) 252 (3):341–345.
   PubMed Web of Science ®Google Scholar
• CODY WL, HE JX, REILY MD et al.: Design of a potentcombined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg1 6 -Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties. J Med. Chem. (1997) 40(102228–2240.
   Google Scholar
• AWANE Y, KUSUMOTO K, KUBO K, KAWATA A, KIKUCHIT, WAKIMASU M: Pharmacological profile in vitro of a new endothelin receptor antagonist, TAK-044. Jpn. Pharmacol (1994) 64 (Suppl. 1) :A0337.
   Google Scholar
• LOVE MP, FERRO CJ, HAYNES WG et al: Endothelinreceptor antagonism in patients with chronic heart failure. Cardiovasc. Res. (2000) 47 (1) :166–172.
   PubMed Web of Science ®Google Scholar
• MIYAHARA T, KOIZUMI T, KUBO K et al: Endothelinreceptor blockade attenuates air embolization-induced pulmonary hypertension in sheep. Eur. Pharmacol (1999) 385 (2-3) :163–169.
   PubMed Web of Science ®Google Scholar
• MAZZE RS, SINNOCK P, DEEB L, BRIMBERRY JL: Anepidemiological model for diabetes mellitus in the United States: five major complications. Diab. Res. Clin. Prac. (1985) 1:185–191.
   PubMedGoogle Scholar
• BLOM ML, GREEN WR, SCHALBAT AP: Diabetic retino-pathy: a review. Del. Med. J. (1994) 66:379–388.
   PubMedGoogle Scholar
• KLEIN R, KLEIN BEK, MOSS SE, DAVIS MD, DEMET DL:Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA (1998) 260:2864–2871.
   Google Scholar
• DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development of long-term complica-tions in insulin-dependent diabetes mellitus. N Engl. J. Med. (1993) 329:977–986.
   PubMed Web of Science ®Google Scholar
• SANTIAGO JV: lessons from the diabetes control and complication trial. Diabetes (1993) 42:1549–1554.
   PubMed Web of Science ®Google Scholar
• KUWABARA T, COGAN DG: Retinal vascular patterns VI. Mural cells of the retinal capillaries. Arch. Ophthalmol (1963) 69:492.
   PubMed Web of Science ®Google Scholar
• MIZUTANI M, KERN TS, LORENZI M: Accelerated death ofretinal microvascular pericytes in human and experimental diabetic retinopathy. j Clin. Invest. (1996) 97:2883–2890.
   PubMed Web of Science ®Google Scholar
• KERN TS, ENGERMAN RL: Comparison of retinal lesionsin allox an-diabetic rats and galactose-fed rats. Curr. Eye Res. (1994) 13:863–867.
   PubMed Web of Science ®Google Scholar
• PORTA M: Endothelium: the main actor in the remodel-ling of the retinal microvasculature in diabetes. Diabetologia (1996) 39:739–744.
   PubMed Web of Science ®Google Scholar
• CERIELLO A: Coagulation activation in diabetesmellitus: the role of hyperglycemia and therapeutic prospects. Diabetologia (1993) 36:1119–1125.
   PubMed Web of Science ®Google Scholar
• CERIELLO A, DELL RUSSO P, ZUCCOTTI C et al.:Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation. A preliminary report. Thromb. Haemostas. (1983) 50:633–634.
   PubMed Web of Science ®Google Scholar
• SHIBA T, BURSELL SE, CLERMONT A, SPORTSMAN R, HEATH W, KING GL: Protein kinase C (PKC) activation is a causal factor for the alteration of retinal blood flow in diabetes of short duration. Invest. Ophthalmol Vis. Sci. (1991) 32 (Suppl.):785–789.
   Google Scholar
• TILTON RG, CHANG K, ALLISON W, WILLIAMSON JR: Comparable diabetes induced increases in retinal blood flow assessed with conventional versus molecular (3H-Desmethylimiprimine) microspheres. Invest. Ophthalmol. Vis. Sci. (1992) 33 (Suppl.):1048–1052.
   Google Scholar
• PUGLIESE G, TILTON RG, WILLIAMSON JR: Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab. Rev. (1991) 7:35–59.
   PubMed Web of Science ®Google Scholar
• TILTON RG, CHANG K, NYENGAARD JR, VAN DM, IDO Y,WILLIAMSON JR: Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozocin-induced diabetic rats. Diabetes (1995) 44:234–242.
   Google Scholar
• TILTON RG, CHANG K, HASAN KS et al.: Prevention ofdiabetic vascular dysfunction by g-uanidines. Inhibi-tion of nitric oxide synthase versus advanced glycation end-product formation. Diabetes (1993) 42:221–232.
   Google Scholar
• TILTON RG, CHANG K, PUGLIESE G et al.: Prevention ofhemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes (1989) 38:1258–1270.
   PubMed Web of Science ®Google Scholar
• HASAN KS, CHANG K, ALLISON W et al.: Glucose-inducedincreases in ocular blood flow are prevented by aminoguanidine and L-NMMA., inhibitors of nitric oxide synthase. Invest. Ophthalmol. Vis. Sci. (1993) 34 (Suppl.):1127–1133.
   Google Scholar
• WILLIAMSON JR, CHANG K, ALLISON W, KILO C: Endoneurial blood flow changes in diabetic rats. Diabet. Med. (1993) 10 (Suppl. 2) :49S–51S.
   Google Scholar
• KUNISAKI M, BURSELL SE, CLERMONT AC et al: Vitamin Eprevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am. J. Physic.' (1995) 269 :E239–E246.
   PubMed Web of Science ®Google Scholar
• CLERMONT AC, BRITTIS M, SHIBA T, MCGOVERN T, KING GL, BURSELL SE: Normalization of retinal blood flow in diabetic rats with primary intervention using insulin pumps. Invest. Ophthalmol. Vis. Sci. (1994) 35:981–990.
   PubMed Web of Science ®Google Scholar
• ISHII H, JIROUSEK MR, KOYA D et al: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science (1996) 272:728–731.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, BURSELL SE, CLERMONT A et al: Vascularendothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes (1997) 46:1473–1480.
   PubMed Web of Science ®Google Scholar
• HOTTA N, KOH N, SAKAKIBARA F et al.: Effect ofpropionyl-L-carnitine on oscillatory potentials in electroretinogram in streptozotocin-diabetic rats. Eur. Pharmacol (1996) 311:199–206.
   PubMed Web of Science ®Google Scholar
• HOTTA N, KOH N, SAKAKIBARA F et al.: Effect of analdose reductase inhibitor on abnormalities of electroretinogram and vascular factors in diabetic rats. Eur. j Pharmacol (1997) 326:45–51.
   PubMed Web of Science ®Google Scholar
• SEGAWA M, HIRATA Y, FUJIMORI S, KADA K: The development of electroretinogram abnormalities and possible roles of polyol pathway activity in diabetic hyperglycemia and galactosemia. Metabolism (1988) 37:454–459.
   PubMed Web of Science ®Google Scholar
• MACGREGOR LC, MATCHINSKY FM: Treatment with an aldose reductase inhibitor or with myo-inositol arrests deterioration of electroretinogram of diabetic rats. J. Clin. Invest. (1985) 76:887–889.
   PubMed Web of Science ®Google Scholar
• HELD PJ, PORT FK, BLAGG CR, AGODA LYC: United Sates Renal Data System 1990 annual report. Am. J Kidney Dis. Suppl. (1990) 2:1–106.
   Google Scholar
• ANDERSEN AR, CHRISTIANSEN JS, ANDERSON JK, KREINER S, DEKERT T: Diabetic neuropathy in Type I (insulin-dependent) diabetes: An epidemiological study. Diabetologia (1983) 25:496–501.
   PubMed Web of Science ®Google Scholar
• BREYER JA, BAIN RP, EVANS JK et al.: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephro-pathy. Kidney Int. (1996) 50:1651–1658.
   PubMed Web of Science ®Google Scholar
• MOGENSEN CE, CHRISTENSEN CK, VITTINGHUS E: The stages in diabetic renal disease. With emphasis in the stage of incipient diabetic neuropathy. Diabetes (1983) 32:64–78.
   PubMed Web of Science ®Google Scholar
• COLTRAN RS, KUMAR V, COLLINS: The Kidney. In:Robbins Pathologic Basis of Disease (6th Edition). Coltran RS, Kumar V, Collins T (Eds.), WB Sanders, Toronto, Canada (1999):966–968.
   Google Scholar
• STEFFES M, PLUTH R, SCHMIDT D, MCCRERY R, BASGEN J, MAUER M: Glomerular and mesangial cell number in insulin dependent diabetes mellitus (IDDM). Proc. Eur. Diabetic Nephropathy Study Group (1996):27.
   Google Scholar
• EPSTEIN FH: Pathophysiology of Progressive nephro-pathies. N Eng]. J. Med. (1998) 339:1448–1456.
   PubMed Web of Science ®Google Scholar
• United Kingdom prospective diabetic study. (1996) Lancet 352:837–853.
   Web of Science ®Google Scholar
• DIABETES CONTROL AND COMPILATIONS RESEARCH GROUP: Effect of intensive therapy. Kidney Int. (1995) 47:1703–1720.
   PubMedGoogle Scholar
• SHARMA K, JIN Y, GUO J, ZIYADEH FN: Anti-TGF-I3 antibody attenuates hypertrophy and ex tracellular matrix gene expression. Diabetes (1996) 45:522–530.
   PubMed Web of Science ®Google Scholar
• THOMAS PK: Diabetic neuropathy: models, mechanisms and mayhem. Can. J. Neuro. ScL (1992) 19:1.
   PubMed Web of Science ®Google Scholar
• BOULTON AJM: Pathogenesis of diabetic neuropathy. In: The Diabetes Annual. Marshall SM, Home PD, Alberti KGMM, Krall LP (Eds.), Elsevier Science Publishers BV (1993) 11:192.
   Google Scholar
• EPSTEIN M, SOWERS JR: Diabetes mellitus and hypertension. Hypertension (1992) 19:403–418.
   PubMed Web of Science ®Google Scholar
• HEDBLAD B, NILSSON P, JANZON L, BERGLUND G: Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabel Med. (2000) 1 7 (4):299–307.
   Google Scholar
• International Diabetes Federation Triennial Report.1991–1994. /DF Brussels (1994).
   Google Scholar
• SAVAGE MP, KROLEWSKI AS, KENIEN GG, LEBEIS MP, CHRISTLIEB AR, LEWIS SM: Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am. J Cardiol (1988) 62:665–669.
   PubMed Web of Science ®Google Scholar
• SHEHADEH A, REGAN TJ: Cardiac consequences of diabetes mellitus. Clin. Cardiol (1995) 18:301–305.
   PubMed Web of Science ®Google Scholar
• LEWINTER MM: Diabetic cardiomyopathy: an overview. Cor. Artery Dis. (1996) 7:95–98.
   PubMed Web of Science ®Google Scholar
• ZHANG WX, CHAKRABARTI S, GREEN DA, SIMA AA: Diabetic autonomic neuropathy in BB rats and effect of ARI treatment on heart rate variability and vag-us structure. Diabetes (1990) 39:613–618.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON JR, CHANG K, FRANGOS M et al.: Perspec-tives in diabetes. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes (1993) 42:801–813.
   PubMedGoogle Scholar
• GREENE DA, STEVENS MJ: The sorbitol-osmotic and sorbitol-redox hypotheses. In: Diabetes Mellitus. Lippin-cott Raven Publishers, Philadelphia, USA (1996):801–809.
   Google Scholar
• KOYA D, KING GL: Protein kinase C activation and the development of diabetic complications. Diabetes (1998) 47:859–866.
   PubMed Web of Science ®Google Scholar
• STEVENS MJ, HOSAKA Y, MASTERSON JA, JONES SM, THOMAS TP, LARKIN DD: Downregulation of the human taurine transporter by glucose in cultured retinal pigment epithelial cells. Am. J Physiol (1999) 277 :E760–E771.
   PubMed Web of Science ®Google Scholar
• KERN TS, KOWLURU RA, ENGERMAN RL: Abnormalitiesof retinal metabolism in diabetes or galactosemia: ATPases and glutathione. Invest. Ophthalmol Vis. (1994) 35:2962–2967.
   PubMed Web of Science ®Google Scholar
• KOWLURU RA, KERN TS, ENGERMAN RL: Abnormalitiesof retinal metabolism in diabetes or experimental galactosemia. W. Antioxidant defense system. Free Radic. Biol. Med. (1997) 22:587–592.
   PubMed Web of Science ®Google Scholar
• WINKLER BS, ARNOLD MJ, BRASSELL MA, SLITER DR: Glucose dependence of glycolysis, hexose monophos-phate shunt activity, energy status and the polyol pathway in retinas isolated from normal (non diabetic) rats. Invest. Ophthalmol. Vis. Sci. (1997) 38:62–71.
   PubMed Web of Science ®Google Scholar
• OBROSOVA IG, SONE H, MASTERSON JA: Evaluation of 131-adrenoceptor antagonist and antioxidant therapy on diabetes-induced changes in retinal NAD(P)-Redox status: Evidence against pseudohypoxia? Diabetes (1998) 47 (Suppl. 1):A40.
   Google Scholar
• NADLER J, WINER L: Free radicals, nitric oxide and diabetic complications. In: Diabetes Mellitus. LeRoith D et al. (Eds.), Lippincott-Raven, Philadelphia, USA (1996):840–848.
   Google Scholar
• WOLFF SP, CRABBE MJC, THORNALLEY PJ: The autoxida-tion of glyceraldehyde and other simple monosaccha-rides. Experientia (1984) 40:244.
   Google Scholar
• HUNT JV, DEAN RT, WOLFF SP: Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem. J. (1988) 256:205–212.
   Google Scholar
• JIANG ZY, WOOLLARD AC, WOLFF SP: Hydrogen peroxide production during experimental protein glycation. FEBS Lett. (1990) 268:69–71.
   PubMed Web of Science ®Google Scholar
• THORNALLEY PJ, WOLFF SP, CRABBE MJ, STERN A: The oxidation of oxyhaemoglobin by glyceraldehyde and other simple monosaccharides. Biochem. 1 (1984) 217:615–622.
   PubMed Web of Science ®Google Scholar
• TAGAMI S, KONDO T, YOSHIDA K, HIROKAWA J, OHTSUKA Y, KAWAKAMI Y: Effect of insulin on impaired antioxidant activities in aortic endothelial cells from diabetic rabbits. Metab. Chn. Exp. (1992) 41:1053–1058.
   PubMed Web of Science ®Google Scholar
• ARAI K, MAGUCHI S, FUJII S, ISHIBASHI H, OIKAWA K,TANIGUCHI N: Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitroglycated site. J. Biol. Chem. (1987) 262:16969–16972.
   PubMed Web of Science ®Google Scholar
• NISHIKAWA T, EDELSTEIN D, DU XL, YAMAGISHI S, MATSUMURA T, KANEDA Y: Normalizing mitochon-drial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 404:787–790.
   PubMed Web of Science ®Google Scholar
• NEWTON AC: Regulation of protein kinase C. Curr. Opin. Cell Biol. (1997) 9:161–167.
   PubMed Web of Science ®Google Scholar
• JOHANNES FJ, PRESTLE J, EIS S, OBERHAGEMANN P, PFIZENMAIER K: PKC is a novel, atypical member of the protein kinase C family. J. Biol. Chem. (1994) 269:6140–6148.
   PubMed Web of Science ®Google Scholar
• LE GOOD JA, ZIEGLER WH, PAREKH DB, ALESSI DR, COHEN P, PARKER PJ: Protein kinase C isotypes controlled by phosphoinositide 3 kinase through the protein kinase PDK1. Science (1998) 281:2042–2045.
   PubMed Web of Science ®Google Scholar
• SHIBA T, INOGUCHI T, SPORTSMAN JR, HEATH WF, BURSELL S, KING GL: Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am. J Physiol (1993) 265:E783–E793.
   PubMed Web of Science ®Google Scholar
• XIA P, INOGUCHI T, KERN TS, ENGERMAN RI, OATES PJ, KING GL: Characterization of the mechanism for the chronic activation of DAG-PKC pathway in diabetes and hypergalactosemia. Diabetes (1994) 43:1122–1129.
   PubMed Web of Science ®Google Scholar
• KOWLURU RA, KERN TS, ENGERMAN RL, ARMSTRONG D: Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxi-dants. Diabetes (1996) 45:1233–1237.
   PubMed Web of Science ®Google Scholar
• LYNCH JJ, FERRO TJ, BLUMENSTOCK FA, BROCKENAUER AM, MALIK AB: Increased endothelial albumin permeability mediated by protein kinase C activation. Clin. Invest. (1990) 85:1991–1998.
   Google Scholar
• SHARMA K, DANOFF TM, DEPIERO A, ZIYADEH FN: Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediation via protein kinase C. Biochem. Biophys. Res. Commun. (1995) 207:80–88.
   PubMed Web of Science ®Google Scholar
• BLAKESLEY VA, LEROTHER D: The role of growth factors in the pathogenesis of diabetic vascular complications. In: Diabetes Mellitus. LeRoith D, Taylor SI, Olefsky M (Eds.), Lippincott-Raven, Philadelphia, USA (1996):824–831.
   Google Scholar
• VLASSARA H: Recent progress in advanced glycation end products and diabetic complications. Diabetes (1997) 46 (Suppl. 2):519–525.
   Google Scholar
• TAKAGI Y, KASHIWAGI A, TANAKA Y, ASAHIAN T, KIKKAWA R, SHIGETA Y: Significance of fructose-induced protein oxidation and formation of advanced glycation end product. J. Diabetes Complications (1995) 9:89–91.
   Google Scholar
• GLOMB MA, MONNIER VM: Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol. Chem. (1995) 270:10017–10026.
   PubMed Web of Science ®Google Scholar
• STITT AW, LI YM, GARDINER TA, BUCALA R, ARCHER DB, VLASSARA H: Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vascula-ture of diabetic and of AGE-infused rats. Am. J Pathol (1997) 150:523–531.
   PubMed Web of Science ®Google Scholar
• STITT AW, HE C, VLASSARA H: Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem. Biophys. Res. Commun. (1999) 256:549–556.
   PubMed Web of Science ®Google Scholar
• MOHAMED AK, BIERHAUS A, SCHIEKOFER S, TRITSCHLER H, ZIEGLER R, NAWROTH PP: The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors (1999) 10:157–167.
   PubMed Web of Science ®Google Scholar
• ESPOSITO C, GERLACH H, BRETT J: Endothelial receptor mediated binding of glucose modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp. Med. (1992) 170:1387–1397.
   Google Scholar
• YAMAGISHI SI, YONEKURA H, YAMAMOTO Y et al.: Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Chem. (1997) 272:8723–8730.
   Google Scholar
• HAITOGLOU CS, TSILIBARY EC, BROWNLEE M, CHARNOIS AS: Altered cellular interaction between endothelial cells and non-enzymatically glucosylated laminin /type IV collagen. J. Biol. Chem. (1992) 267:12404–12407.
   PubMed Web of Science ®Google Scholar
• BUCALA R, TRACEY KJ, CERAMI A: Advanced glycosyla-tion products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. Diabetologia (1991) 87:432.
   Google Scholar
• GIARDINO I, EDELSTEIN D, BROWNLEE M: BCL-2 expres-sion or antoxidants prevent hyperglycemia-induced formation of intracellular advanced glycation end products in bovine endothelial cells. J Chn. Invest. (1996) 97:1422–1428.
   PubMed Web of Science ®Google Scholar
• HOPFNER RL, GOPALAKRISHNAN V: Endothelin: emerging role in diabetic vascular complications. Diabetologia (1999) 42:1383–1394.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI T, OHNAKA K, TAKAYANAGI R, UMEDA F, NAWATA H: Enhanced secretion of endothelin_1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett. (1990) 267:16–18.
   PubMed Web of Science ®Google Scholar
• CHEN S, APOSTOLOVA M, CHERIAN G, CHAKRABARTI S: Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells. Lab. Invest. (2000) 80:1311–1321.
   PubMed Web of Science ®Google Scholar
• HU RM, LEVIN ER, FRANK HJL: Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes (1993) 42:351–358.
   PubMed Web of Science ®Google Scholar
• WAKASAKI H, KOYA D, SCHOEN FJ et al: Targeted overexpression of protein kinase C2 isoform in myocardium causes cardiomyopathy. Proc. Natl. Acad. Sci. USA (1997) 94:9320–9325.
   PubMed Web of Science ®Google Scholar
• VANHOUTTE PM: Endothelin-1. A matter of life and breath. Nature (1994) 368:693–694.
   Google Scholar
• MATSUURA A, KAWASHIMA S, YAMOCHI W et al.: Vascular endothelial growth factor increases endothelin-converting enzyme expression in vascular endothelial cells. Biochem. Biophys. Res. Commun. (1997) 235:713–716.
   PubMed Web of Science ®Google Scholar
• PEDRAM A, RAZANDI M, HU RM, LEVIN ER: Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol. Chem. (1997) 27:17097–17103.
   Google Scholar
• QUEHENBERGER P, BIERHAUS A, FASCHING P, MUELLNER C, KLEVESATH M, HONG M: Endothelin 1 transcription is controlled by nuclear factor-KB in AGE-stimulated cultured endothelial cells. Diabetes (2000) 49:1561–1570.
   PubMed Web of Science ®Google Scholar
• CHAKRABARTI S, SIMA AAF: Endothelin-1 and Endothelin-3 like immunoreactivity in the eyes of diabetic and non-diabetic BB/W rats. Diab. Res. Clin. Prac. (1997) 37:109–120.
   PubMed Web of Science ®Google Scholar
• CHAKRAVARTHY U, DOUGLASAJ, BAILIE R, MCKIBBEN B, ARCHER DB: Immunoreactive endothelin distribution in ocular tissue. Invest. Ophthalmol. Vis. Sci. (1997) 35:2448–2454.
   Google Scholar
• CHAKRABARTI S, GAN XT, MERRY A, KARMAZYN M, SIMA AAF: Augmented retinal endothelin-1, endothelin-3, EndothelinA and EndothelinB gene expression in chronic diabetes. Curr. Eye Res. (1998) 17:301–307.
   PubMed Web of Science ®Google Scholar
• TAKAGI C, BURSELL SE, UN YVV et al.: Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest. Ophthalmol Vis. Sci. (1996) 37:2504–2518.
   PubMed Web of Science ®Google Scholar
• DENG DX, EVANS T, MUKHERJEE K, DOWNEY D, CHAKRABARTI S: Diabetes induced dysfunction in the retina: role of endothelins. Diabetologia (1999) 42:1228–1234.
   PubMed Web of Science ®Google Scholar
• EVANS T, DENG DX, MUKHERJEE K, DOWNEY D, CHAKRABARTI S: Endothelins, their receptors and retinal vascular dysfunction in galactose-fed rats. Diabetes Res. Clin. Pract. (2000) 48:75–85.
   PubMed Web of Science ®Google Scholar
• EVANS T, DENG DX, CHEN S, CHAKRABARTI S: En dothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose fed rats. Diabetes (2000) 49:662–666.
   PubMed Web of Science ®Google Scholar
• KAWAMURA M, OHGAWARA H, NARUSE M et al.: Increased plasma endothelin in NIDDM patients with retinopathy. Diabetes Care (1992) 15:1396–1397.
   PubMed Web of Science ®Google Scholar
• OGATA M, NARUSE M, IWASAKI N et al: Immunor eactiv e endothelin levels in the vitreous fluid are decreased in diabetic patients with proliferative retinopathy. Cardiovasc. Pharmacol (1998) 31 (Suppl. 1):S378–S379.
   Google Scholar
• SIMONSON MS: Endothelins: multifunctional renal peptides. Physiol. Rev. (1993) 73:375–411.
   PubMed Web of Science ®Google Scholar
• TURNER NC, MORGAN PJ, HAYNES AC et al: Elevated renal endothelin-1 clearance and mRNA levels associ-ated with albuminuria and nephropathy in non-insulin dependent diabetes mellitus studies in obese fa/fa Zucker rats. an. Sci. (1997) 93:565–571.
   Google Scholar
• KHAN MA, DASHVVOOD MR, THOMPSON CS, MUMTAZ FH, MIKHAILIDIS DP, MORGAN RJ: Time-dependent up-regulation of endothelin-A receptors and down-regulation of endothelin-B receptors and nitric oxide synthase binding sites in the renal medulla of a rabbit model of partial bladder outlet obstruction: potential clinical relevance. BJU Int. (1999) 84 (9):1073–1080.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, EBIHARA I, FUKUI M, TOMINO Y, KOIDA H: Effect of a specific endothelin-Areceptor antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes (1995) 44:895–899.
   PubMed Web of Science ®Google Scholar
• ISHIMURA E, SHOUP S, NISHIZAWA Y, MORII H, KASHGARIAN M: Regulation of mRNA expression for ECM by cultured rat mesangial cells. J. Am. Soc. Nephrol (1991) 2:546.
   Google Scholar
• SUZUKI T, KUMAZAKI T, MITSUI Y: Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem. Biophys. Res. Commun. (1993) 191:823–830.
   PubMed Web of Science ®Google Scholar
• CHUA BH, CHUA CC, DIGLIO CA, SIU BB: Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochem. Biophys. Acta (1993) 1178:201–206.
   PubMed Web of Science ®Google Scholar
• FUKUCHI M, GIAID A: Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts. J. Cardiovasc. Pharmacol. (1998) 31 (Suppl. 0:5421–423
   Google Scholar
• HU JR, VON HARSDORF R, LANG RE: Endothelin has potent inotropic effects in rat atria. Eur. j Pharmacol. (1988) 158:275–278.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA T, YANAGISAWA M, KIMURA S, GOTO K, MASAKI T: Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictor peptide. Pflugers Arch. (1988) 413:108–110.
   PubMed Web of Science ®Google Scholar
• KARMAZYN M: The role of endothelins in cardiac function in health and disease. In: Myocardial Ichaemia: Mechanisms, Reperfusion, Protection. Karmazyn M (Ed.), Birkhauser, Basel, Switzerland (1996):209–230.
   Google Scholar
• LIN YW, DUH E, JIANG Z: Expression of preproEndothelin-1 mRNA in streptozotocin-induced diabetic rats. Diabetes (1996) 45 (Suppl. 2):48A.
   Google Scholar
• VESCI L, MATTERA GG, TOBIA P, CORSICO N, CALVANI M: Cardiac and renal endothelin-1 binding sites in streptozotocin-induced diabetic rats. Pharmacol. Res. (1995) 32:363–367
   PubMed Web of Science ®Google Scholar
• LIEU AT, REID JJ: Changes in the responsiveness to endothelin-1 in isolated atria from diabetic rats. Eur. Pharmacol. (1994) 261:33–42.
   PubMed Web of Science ®Google Scholar
• CHEN S, EVANS T, MUKHERJEE K, KARMAZYN M, CHAKRABARTI S: Diabetes-induced myocardial structural changes: Role of endothelin-1 and its receptors. j Mot. Cell Cardiol. (2000) 32(9):1621–1629.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ AC, PATINO R, IBARRA J et al.: Endothelin in hypertension and diabetes mellitus. In: Endothelin in Cardiovascular Diseases. Luscher TF (Ed.), Springer, Berlin Heidelberg, New York, USA (1995):157–170.
   Google Scholar
• PERFETTO F, TARQUINI R, DE LEOBARDIS V et al.: Vascular damage and not hypertension per se influences endothelin-1 plasma levels in patients with non insulin dependent diabetes mellitus. Recent Prog. Med. (1997) 88:317–320.
   Google Scholar
• SIMA AAF, SUGIMOTO K: Experimental diabetic neuropathy: an update. Diabetologia (1999) 42:773–788.
   PubMed Web of Science ®Google Scholar
• ZHU X, EICHBERG J: 1,2-diacylglycerol content and its arachidonyl-containing molecular species are reduced in sciatic nerve from streptozotocin-induced diabetic rats. J. Neurochem. (1990) 55:1087–1090.
   PubMed Web of Science ®Google Scholar
• HERMENEGILDO C, FELIPO V, MINANA MD, ROMERO FJ, GRISOLIA S: Sustained recovery of Na±/K+-ATPase activity in sciatic nerve of diabetic mice by administration of H7 or callphostin C, inhibitors of protein kinase C. Diabetes (1993) 42:257.
   PubMed Web of Science ®Google Scholar
• CAMERON NE, DINES KC, COTTER MA: The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin diabetic rats. Diabetologia (1994) 37:1209–1215.
   PubMed Web of Science ®Google Scholar
• STEVENS EJ, TOMLINSON DR: Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes. Br. J. Pharmacol. (1995) 115:373–379.
   PubMed Web of Science ®Google Scholar
• DENG D, EVANS T, XU G, SIMA AAF, CHAKRABARTI S: Endothelin-1 and its receptors in the pathogenesis of neuronal and retinal functional abnormalities in the diabetic rats. Proceedings of the 58th Scientific Sessions on Diabetes. Chicago, USA (1998):0559.
   Google Scholar
• TERTIN-CLARY C, EUDE I, FOURNIER T, PARIS B, BREUILLER-FOUCHE M, FERRE F: Contribution of protein kinase C to KU-1-induced proliferation in human myometrial cells. Am. J. Physiot (1999) 276(3 Pt 0:503–511.
   Google Scholar
• CATALAN RE, MARTINEZ AM, ARAGONES MD et al.: Endothelin-stimulated phosphoinositide turnover and protein kinase C translocation in rat synapto-somes. Biochem. Mot. Biol. mt. (1996) 38:7–14.
   PubMedGoogle Scholar
• KAWAI N, YAMAMOTO T, YAMAMOTO H, MCCARRON RM, SPATZ M: Endothelin 1 stimulates Na+, K(+)-ATPase and Na(+)-K(+)-C1-cotransport through ETA receptors and protein kinase C-dependent pathway in cerebral capillary endothelium. J. Neurochem. (1995) 65:1588–1596.
   PubMed Web of Science ®Google Scholar
• ROSEN P, BALLHAUSEN T, BLOCH W, ADDICKS K: Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as antioxidant. Diabetologia (1995) 38:1157–1168.
   PubMed Web of Science ®Google Scholar
• FAURE V, COURTOIS Y, GOUREAU 0: Differential regulation of nitric oxide synthase-II mRNA by growth factors in rat, bovine and human retinal pigmented epithelial cells. Ocul. Immunol. Inflamm. (1999) 7:27–34.
   PubMed Web of Science ®Google Scholar
• HASDAI D, HOLMES DR, JR., RICHARDSON DM, IZHAR U, LERMAN A: Insulin and IGF-I attenuate the coronary vasoconstrictor effects of endothelin-1 but not of sarafotoxin 6c. Cardiovasc. Res. (1998) 39:644–650.
   Google Scholar
• GHISO N, ROHAN RM, AMANO S, GARLAND R, ADAMIS AP: Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. Invest. Ophthalmol. Vis. Sci. (1999) 40:1033–1039.
   PubMed Web of Science ®Google Scholar